TY  - GEN
AU  - Thorarensen,Atli
AU  - Dowty,Martin E
AU  - Banker,Mary Ellen
AU  - Juba,Brian
AU  - Jussif,Jason
AU  - Lin,Tsung
AU  - Vincent,Fabien
AU  - Czerwinski,Robert M
AU  - Casimiro-Garcia,Agustin
AU  - Unwalla,Ray
AU  - Trujillo,John I
AU  - Liang,Sidney
AU  - Balbo,Paul
AU  - Che,Ye
AU  - Gilbert,Adam M
AU  - Brown,Matthew F
AU  - Hayward,Matthew
AU  - Montgomery,Justin
AU  - Leung,Louis
AU  - Yang,Xin
AU  - Soucy,Sarah
AU  - Hegen,Martin
AU  - Coe,Jotham
AU  - Langille,Jonathan
AU  - Vajdos,Felix
AU  - Chrencik,Jill
AU  - Telliez,Jean-Baptiste
TI  - Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
SN  - 1520-4804
PY  - 2017///0807
KW  - Administration, Oral
KW  - Drug Design
KW  - Humans
KW  - Janus Kinase 3
KW  - antagonists & inhibitors
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Pyrimidines
KW  - Pyrroles
KW  - Signal Transduction
KW  - drug effects
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S
UR  - https://doi.org/10.1021/acs.jmedchem.6b01694
ER  -